FDA Issues Guidance on Responding to Form 483 Observations Following Drug CGMP Inspections
FDA Issues Guidance on Responding to Form 483 Observations Following Drug CGMP Inspections FDA Releases Guidance on Responding to Form 483 Observations The U.S. Food and Drug Administration has issued a guidance document titled “Responding to FDA Form 483 Observations...
FDA Announces Public Meeting on Dietary Supplement Innovation and Ingredient Scope
FDA Announces Public Meeting on Dietary Supplement Innovation and Ingredient Scope FDA to Hold Public Meeting on Dietary Supplement Innovation and Ingredient Scope The U.S. Food and Drug Administration has announced an upcoming public meeting focused on dietary...
Why Food Recalls Are Increasing — And What Companies Must Do Differently
Food recalls are increasing despite stronger regulations and expanded food safety systems. In this Issue of the Month, EAS consultant Amandeep Dhillon examines the systemic causes behind this trend and what companies must do differently to reduce risk.
EAS Expands Services: Biologics and Biosimilars Consulting
EAS Expands Services: Biologics and Biosimilars Consulting EAS Consulting Group is pleased to announce the expansion of our service offerings to include Biologics and Biosimilars regulatory and quality consulting. As these products continue to play an increasingly...